Want to see RELL full AI Analyst Report?
Net Sales by Segment
Revenue generated by each business unit, showing which segments are growing or shrinking and where the company earns most of its sales. Useful for spotting concentration risk, exposure to cyclical markets like industrial, energy, or defense, and whether Richardson is expanding higher-value product lines or relying on commodity distribution.Healthcare has effectively been removed from the top line after the divestiture, concentrating growth in PMT as the primary revenue engine while Canvas and GES are maturing as project‑based contributors. Management’s sizable backlog and FY guidance point to durable PMT momentum and double‑digit GES growth ahead, but quarter‑to‑quarter volatility remains as project timing can lag backlog realization, and a large inventory build tied to a critical supplier is a near‑term cash drag despite improving margins and a return to profitability.
Date | Healthcare | PMT | GES | Canvys |
|---|---|---|---|---|
Jun 30, 2026 | $0.00 | $47.49M | $6.46M | $12.26M |
Mar 31, 2026 | $0.00 | $38.73M | $8.79M | $7.95M |
Dec 31, 2025 | $0.00 | $35.21M | $8.30M | $8.78M |
Sep 30, 2025 | $0.00 | $39.07M | $7.26M | $8.28M |
Jun 30, 2025 | $1.13M | $35.94M | $5.36M | $9.46M |
Mar 31, 2025 | $2.09M | $33.22M | $9.30M | $9.20M |
Dec 31, 2024 | $2.27M | $34.40M | $5.97M | $6.85M |
Sep 30, 2024 | $3.80M | $34.20M | $8.09M | $7.64M |
Jun 30, 2024 | $3.50M | $30.50M | $4.70M | $8.67M |
Mar 31, 2024 | $3.09M | $31.16M | $11.53M | $6.59M |